Chen et al., 2025 - Google Patents
FAP-targeted radioligand therapy with 68Ga/177Lu-DOTA-2P (FAPI) 2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacyChen et al., 2025
View HTML- Document ID
- 9305162126733711258
- Author
- Chen J
- Zhou Y
- Pang Y
- Fu K
- Luo Q
- Sun L
- Wu H
- Lin Q
- Su G
- Chen X
- Zhao L
- Chen H
- Publication year
- Publication venue
- Journal for Immunotherapy of Cancer
External Links
Snippet
Background Fibroblast activation protein (FAP)-targeted radioligand therapy, with immunomodulatory effects, has shown efficacy in both preclinical and clinical studies. We recently reported on a novel dimeric FAP-targeting radiopharmaceutical, 68Ga/177Lu-DOTA …
- 230000000259 anti-tumor effect 0 title abstract description 40
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kristensen et al. | CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models | |
| Jiang et al. | Progress and challenges in precise treatment of tumors with PD-1/PD-L1 blockade | |
| Genova et al. | Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade | |
| Minn et al. | Enhancing CAR T-cell therapy through cellular imaging and radiotherapy | |
| Huang et al. | Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer | |
| Barton et al. | Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer | |
| Streby et al. | Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I‐mIBG therapy | |
| Yang et al. | Progresses and perspectives of anti-PD-1/PD-L1 antibody therapy in head and neck cancers | |
| Zhou et al. | Validating the pivotal role of the immune system in low‐dose radiation‐induced tumor inhibition in Lewis lung cancer‐bearing mice | |
| Balmaceda et al. | Multi‐institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high‐grade gliomas | |
| Zhang et al. | CAR-T cells in the treatment of ovarian cancer: A promising cell therapy | |
| Chang et al. | Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers | |
| Wu et al. | Phase I study of zotiraciclib in combination with temozolomide for patients with recurrent high-grade astrocytomas | |
| Yoshii et al. | 64Cu-ATSM therapy targets regions with activated DNA repair and enrichment of CD133+ cells in an HT-29 tumor model: sensitization with a nucleic acid antimetabolite | |
| Vo et al. | Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia | |
| Oweida et al. | Hypofractionated radiotherapy is superior to conventional fractionation in an orthotopic model of anaplastic thyroid cancer | |
| Baiu et al. | Targeted molecular radiotherapy of pediatric solid tumors using a radioiodinated alkyl-phospholipid ether analog | |
| Kunikowska et al. | Targeted alpha therapy for glioblastoma | |
| Ertveldt et al. | Targeted radionuclide therapy with low and high-dose lutetium-177–labeled single domain antibodies induces distinct immune signatures in a mouse melanoma model | |
| Xie et al. | A 211At-labelled mGluR1 inhibitor induces cancer senescence to elicit long-lasting anti-tumor efficacy | |
| Crotty et al. | Considerations when treating high-grade pediatric glioma patients with immunotherapy | |
| Nyati et al. | A phase I clinical trial of oncolytic adenovirus mediated suicide and interleukin-12 gene therapy in patients with recurrent localized prostate adenocarcinoma | |
| WO2023217109A1 (en) | Combination of m6a rna methylase inhibitor and immune checkpoint inhibitor for treating tumors | |
| Melzig et al. | Combined external beam radiotherapy with carbon ions and tumor targeting endoradiotherapy | |
| Lukas et al. | Immune priming with spatially fractionated radiation therapy |